Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by Ciaoon Feb 15, 2024 10:52pm
83 Views
Post# 35883430

RE:Pro-forma financials

RE:Pro-forma financials
lscfa wrote: Gagnon blew $6.7M of cash on this lousy merger......

4 (d) To reflect the payment of $2,766,181 estimated non-recurring incremental transaction costs of Ceapro, including banking, printing, legal and accounting services which are incremental cost of the Transaction, that are not recorded in its September 30, 2023 financial statements as an increase to general and administrative expense as if the transactions had occurred on September 30, 2023. The transaction is not expected to have a recurring impact. 

 

4 (e)    To reflect the payment of $3,949,398 estimated non-recurring incremental transaction costs of Aeterna Zentaris, including banking, printing, legal and accounting services which are incremental cost of the Transaction, that are not recorded in its September 30, 2023 financial statements as an increase to general and administrative expense as if the transactions had occurred on September 30, 2023. The transaction is not expected to have a recurring impact. 

 

 



Now I understand the sense of desparation in the NR today where an anonymous director asks to vote yes as time is short.

The costs for this M&A seem very high.
https://www.ey.com/en_us/strategy-transactions/four-current-trends-estimating-mergers-acquisitions-integration-costs#:~:text=M%26A%20transaction%20costs%20can%20range,according%20to%20the%20EY%20analysis.

does 4(e) indicate we are paying AEZS share of legal fees and costs? 

So Gilles is burning down the company and in a sense he could be using this point of depleted cash reserves now to push the merger through?
<< Previous
Bullboard Posts
Next >>